Noonan syndrome
MONDO:0018997Noonan Syndrome (NS) is characterized by short stature, typical facial dysmorphism and congenital heart defects.
Also known as: Noonan syndrome, Noonan's syndrome, Noonan-Ehmke syndrome, Ullrich-Noonan syndrome, pseudo-Ullrich-Turner syndrome
34 clinical trials for this condition and its sub-types, 21 tagged with Noonan syndrome itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
Sub-types of Noonan syndrome
-
Noonan syndrome 3 2 trials
-
Noonan syndrome 5 1 trial
-
Noonan syndrome 1 0 trials
-
Noonan syndrome 10 0 trials
-
Noonan syndrome 11 0 trials
-
Noonan syndrome 13 0 trials
-
Noonan syndrome 14 0 trials
-
Noonan syndrome 2 0 trials
-
Noonan syndrome 4 0 trials
-
Noonan syndrome 6 0 trials
-
Noonan syndrome 7 0 trials
-
Noonan syndrome 8 0 trials
-
Noonan syndrome 9 0 trials
-
Noonan syndrome 12 0 trials
-
Weekly shot may help short kids grow – new study underway
Disease control OngoingThis study tests a new growth hormone medicine called somapacitan, given once a week, in 47 children who are very short due to being born small for gestational age, or having Turner syndrome, Noonan syndrome, or idiopathic short stature. The main goal is to see if it is safe and …
Phase 3 • Sponsor: Novo Nordisk A/S • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
Weekly shot could replace daily needles for kids with growth disorders
Disease control OngoingThis study tests if a new growth hormone medicine (somapacitan) given once a week works as well as the standard daily growth hormone (Norditropin) for children who are very short due to being born small, or having Turner syndrome, Noonan syndrome, or unknown causes. About 412 chi…
Phase 3 • Sponsor: Novo Nordisk A/S • Aim: Disease control
Last updated Jun 27, 2026 13:08 UTC
-
New drug aims to help kids with rare genetic short stature grow taller
Disease control OngoingThis study tests a drug called vosoritide in 56 children with short stature caused by certain genetic conditions. The drug targets the growth plate to help children grow faster. Participants are observed for 6 months, then treated with daily injections for 12 months to check safe…
Phase 2 • Sponsor: Andrew Dauber • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
New program aims to ease burden on families of kids with rare diseases
Symptom relief By invitation onlyThis study tests a program called FACE-Rare, designed to support family caregivers of children with rare, life-limiting diseases. The program includes three sessions to help families prepare for future medical decisions and improve their quality of life. Researchers will compare …
Sponsor: Children's National Research Institute • Aim: Symptom relief
Last updated Jun 27, 2026 09:00 UTC
-
New registry to monitor growth hormone treatment in kids with rare condition
Knowledge-focused By invitation onlyThis study is a registry that will follow up to 221 children with Noonan Syndrome who are already taking or starting Norditropin® for short stature. Researchers will collect information on growth, side effects, and quality of life over time. No new treatment is being tested—the g…
Sponsor: Novo Nordisk A/S • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:51 UTC